Targeted radiopharmaceuticals offer resistance-free potency, pre-treatment imaging and widespread combination potential. Big pharma and investors are piling in.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

References
Nguyen, T. D. et al. Cancers https://doi.org/10.3390/cancers15030713 (2023).
Strosberg, J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1607427 (2017).
Sartor, O. et al. N. Engl. J. Med. 385, 1091–1103 (2021).
Sgouros, G. Adv. Drug Del. Rev. https://doi.org/10.1016/j.addr.2008.04.007 (2008).
Corso, C. D. et al. Am. J. Cancer Res. 1, 390–412 (2011).
Cappon, D. J. et al. Health Phys. https://doi.org/10.1097/HP.0000000000001644 (2023).
Jang, A., Kendi, A. T., Johnson, G. B., Halfdanarson, T. R. & Sartor, O. Int. J. Mol. Sci. https://doi.org/10.3390/ijms241411626 (2023).
Shi, M. et al. Front. Med https://doi.org/10.3389/fmed.2022.1034315 (2022).
Li, M. et al. Cancers https://doi.org/10.3390/cancers13153676 (2021).
Kerr, C. P. et al. Pharmaceutics https://doi.org/10.3390/pharmaceutics15010128 (2023).
Fitzgerald, A. A. & Weiner, L. M. Cancer Metastasis Rev. 39, 783–803 (2020).
Khan, S. et al. Int. J. Health Sci. (Qassim) 4, 39–46 (2010).
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M. & Lewis, J. S. Nat. Rev. Clin. Oncol. 19, 534–550 (2022).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Precision radiation opens a new window on cancer therapy. Nat Biotechnol 42, 1003–1008 (2024). https://doi.org/10.1038/s41587-024-02295-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-024-02295-z
This article is cited by
-
Biopharma deals get smaller and earlier
Nature Biotechnology (2025)
-
Radiopharma pipeline builds ahead of key data
Nature Cancer (2025)
-
Covalent multi-targeted radiopharmaceuticals for enhanced tumor theranostics
Science China Chemistry (2025)
-
DNA damage repair inhibitors boost targeted radionuclide therapy and immunotherapy of prostate cancer
Apoptosis (2025)